IMDX - NASDAQ

Insight Molecular Diagnostics Inc.

IMDX·NASDAQ

$6.03

+6.3%

HealthcareMedical - Diagnostics & Research

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$161.85M

EPS-1.6500

P/E Ratio-3.65

Earnings Date08/10/2026

imdx

Selling, General and Administrative Expenses

Last Annual Value

16.98M

3-Year CAGR

-8%

5-Year CAGR

-6%

10-Year CAGR

15%

Adjust for Inflation

Insight Molecular Diagnostics Inc. Competitors Analysis of Selling, General and Administrative Expenses

IMDX · NASDAQ

Company	Selling, General and Administrative Expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Insight Molecular Diagnostics Inc. NASDAQ:IMDX	16.98M	8.5%	-3.6%	12.0%
PepGen Inc. NASDAQ:PEPG	22.57M	10.7%	22.7%	N/A
Agenus Inc. NASDAQ:AGEN	44.39M	-17.4%	-10.3%	3.0%
Inovio Pharmaceuticals, Inc. NASDAQ:INO	32.68M	-11.8%	-9.5%	3.2%
Opus Genetics, Inc. NASDAQ:IRD	21.98M	22.5%	22.0%	N/A
Metagenomi, Inc. Common Stock NASDAQ:MGX	26.79M	-2.4%	22.5%	N/A
Nautilus Biotechnology, Inc. NASDAQ:NAUT	25.73M	-3.8%	4.0%	N/A
Seer, Inc. NASDAQ:SEER	42.58M	-10.3%	0.2%	N/A
Surrozen, Inc. NASDAQ:SRZN	16.20M	0.8%	2.7%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	31.99M	7.9%	18.3%	N/A
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL	37.72M	-14.0%	-1.6%	N/A

Insight Molecular Diagnostics Inc. Fair Value Envelope

IMDX · NASDAQ

Our analysis suggests that IMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.03, this represents a potential HIDDEN relative to our calculated worth for Insight Molecular Diagnostics Inc..

HIDDEN

Intrinsic Value

Current Price: $6.03

Related Guides

Blog Categories

Continue your IMDX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.